- Cancer immunotherapies developer Scancell said it had signed a second collaboration and non-exclusive research agreement, this time with a Chinese biotechnology company, which it didn't name.

The agreement would involve the two companies assessing monoclonal antibodies targeting tumour-associated glycans that havd been enhanced with the company's AvidiMa technology.

The new collaboration partner would conduct pre-clinical studies to evaluate Scancell's anti-TaG mAbs, including those enhanced with AvidiMab, for the treatment of cancer.

'As previously stated, we believe our novel AvidiMab platform and tumour associated glycan antibodies have broad partnering potential and this has been further demonstrated by today's agreement, the second in four months,' chief executive Cliff Holloway said.

'This is our first collaboration in China, and we look forward to updating the market on further progress with this platform in due course.'

Story provided by